NCT01848470 - Multiple Ascending Doses Study of CG400549 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Healthy

Interventions

DRUG

CG400549 640mg

multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state

DRUG

CG400549 320 mg

multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state

DRUG

CG400549 640 mg

multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state

DRUG

CG400549 960 mg

multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state

DRUG

Placebo 640mg

multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state

DRUG

Placebo 320mg

multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state

DRUG

placebo 960 mg

multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state

DRUG

Placebo 640mg

multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state

Trial Locations (1)

PRA International clinical center, Zuidlaren